2025 Q3 -tulosraportti
47 päivää sittenTarjoustasot
Euronext Growth Oslo
Määrä
Osto
382 768
Myynti
Määrä
189 300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 902 | - | - | ||
| 40 000 | - | - | ||
| 12 818 | - | - | ||
| 58 442 | - | - | ||
| 200 000 | - | - |
Ylin
0,075VWAP
Alin
0,072VaihtoMäärä
0,5 6 543 851
VWAP
Ylin
0,075Alin
0,072VaihtoMäärä
0,5 6 543 851
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 25.3. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 26.11.2025 | |
| 2025 Q2 -tulosraportti | 17.9.2025 | |
| 2025 Q1 -tulosraportti | 27.6.2025 | |
| 2024 Q4 -tulosraportti | 26.3.2025 | |
| 2024 Q3 -tulosraportti | 27.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10 t sittenhttps://medwatch.no/nyheter/legemidler_biotek/article18894010.ece Article today 👌 Paywall, so attaching for those interested 👏 Spun-off companies. Change of main focus. Hard cost cuts. Now the management of Softox Solutions hopes to put some turbulent years behind them. The biotechnology company was established in 2012 and got a new CEO in 2024, when Thomas Bjarnsholt took office. The same year, biotech veteran Ulrik Spork took over as chairman of the board. In this interview, they explain why the company saw the need for a comprehensive strategic reorientation. The biggest change for the company was a change in the main indication the company wanted to test its platform on. From the acute disease ventilator-associated pneumonia (VAP) to the chronic cystic fibrosis. Both are diseases that affect our lungs. – Overall, we believe that the company can deliver on both chronic and acute indications. The challenge with acute lung patients is that they are very ill, often unconscious, and there are many complex factors that affect the picture, says chairman Spork. He says that when they analyzed the company's situation, there were too many uncertainties with VAP. – Should we risk a more expensive and longer study to reach an uncertain endpoint? Or should we go for more well-defined patient groups to prove the platform's effect? It was simply safer to go for cystic fibrosis. In addition, there are 20 years of experience with clinical studies within the disease, and patients can cough up samples that make it easier to measure whether Softox's solution actually kills bacteria. – It was about practical things that perhaps had not been thoroughly enough considered previously.
- ·1 päivä sittenhttps://docs.google.com/document/u/0/d/1sabf0reYnNUlkHiC2bG1EquCLwOxtgY16e-wecFsDRM/mobilebasic?pli=1 Interesting reading, taken from FA👌
·13 t sittenFantastic, I've been saying that for a long time, if this breaks through/people understand how groundbreaking this is for humanity then this will explode, not just for my sake but humanity in general, but it helps that it helps me🍾, anyway have a nice day and good luck and take care of each other ❤️❤️ 
1 päivä sitten1 päivä sitten
·3 päivää sittenGot chat gpt to review various documents for SoftOx and create an analysis. A lottery stock that can actually succeed during 2026. Scenario Analysis 2026–2027 (straight to the point) Phase 2a fails / unclear signal Probability: ~25 % Price: 0.03–0.05 What happens: Lung is difficult The market loses faith Classic biotech slaughter This is the downside. It is ugly, but limited. Phase 2a OK / positive, but not wow Probability: ~45 % Price: 0.20–0.35 What happens: Repricing, not hype New floor in the stock SoftOx becomes a “real company”, not hope . Phase 2a clearly positive + military contract Probability: ~25 % Price: 0.50–1.00+ What happens: EU/NATO-stockpiling De-risking deluxe Big Pharma starts to smell money this is the jackpot scenario. Not sci-fi. Full success (rare, but possible) Probability: ~5 % Price: 1.50–3.00 What happens: Partner agreement Global AMR-case
·2 päivää sittenWhat does it base the probability of failure on/how is it prompted in this case? Has it taken into account that SoftOx has already completed phase 2a on SBE, successfully? The research on SIS is based on the same chemistry/composition, and chemistry tends to remain similar through phases from 2a-3a, in several such cases as this case is based on.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
47 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10 t sittenhttps://medwatch.no/nyheter/legemidler_biotek/article18894010.ece Article today 👌 Paywall, so attaching for those interested 👏 Spun-off companies. Change of main focus. Hard cost cuts. Now the management of Softox Solutions hopes to put some turbulent years behind them. The biotechnology company was established in 2012 and got a new CEO in 2024, when Thomas Bjarnsholt took office. The same year, biotech veteran Ulrik Spork took over as chairman of the board. In this interview, they explain why the company saw the need for a comprehensive strategic reorientation. The biggest change for the company was a change in the main indication the company wanted to test its platform on. From the acute disease ventilator-associated pneumonia (VAP) to the chronic cystic fibrosis. Both are diseases that affect our lungs. – Overall, we believe that the company can deliver on both chronic and acute indications. The challenge with acute lung patients is that they are very ill, often unconscious, and there are many complex factors that affect the picture, says chairman Spork. He says that when they analyzed the company's situation, there were too many uncertainties with VAP. – Should we risk a more expensive and longer study to reach an uncertain endpoint? Or should we go for more well-defined patient groups to prove the platform's effect? It was simply safer to go for cystic fibrosis. In addition, there are 20 years of experience with clinical studies within the disease, and patients can cough up samples that make it easier to measure whether Softox's solution actually kills bacteria. – It was about practical things that perhaps had not been thoroughly enough considered previously.
- ·1 päivä sittenhttps://docs.google.com/document/u/0/d/1sabf0reYnNUlkHiC2bG1EquCLwOxtgY16e-wecFsDRM/mobilebasic?pli=1 Interesting reading, taken from FA👌·13 t sittenFantastic, I've been saying that for a long time, if this breaks through/people understand how groundbreaking this is for humanity then this will explode, not just for my sake but humanity in general, but it helps that it helps me🍾, anyway have a nice day and good luck and take care of each other ❤️❤️
- 1 päivä sitten1 päivä sitten
- ·3 päivää sittenGot chat gpt to review various documents for SoftOx and create an analysis. A lottery stock that can actually succeed during 2026. Scenario Analysis 2026–2027 (straight to the point) Phase 2a fails / unclear signal Probability: ~25 % Price: 0.03–0.05 What happens: Lung is difficult The market loses faith Classic biotech slaughter This is the downside. It is ugly, but limited. Phase 2a OK / positive, but not wow Probability: ~45 % Price: 0.20–0.35 What happens: Repricing, not hype New floor in the stock SoftOx becomes a “real company”, not hope . Phase 2a clearly positive + military contract Probability: ~25 % Price: 0.50–1.00+ What happens: EU/NATO-stockpiling De-risking deluxe Big Pharma starts to smell money this is the jackpot scenario. Not sci-fi. Full success (rare, but possible) Probability: ~5 % Price: 1.50–3.00 What happens: Partner agreement Global AMR-case·2 päivää sittenWhat does it base the probability of failure on/how is it prompted in this case? Has it taken into account that SoftOx has already completed phase 2a on SBE, successfully? The research on SIS is based on the same chemistry/composition, and chemistry tends to remain similar through phases from 2a-3a, in several such cases as this case is based on.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
382 768
Myynti
Määrä
189 300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 902 | - | - | ||
| 40 000 | - | - | ||
| 12 818 | - | - | ||
| 58 442 | - | - | ||
| 200 000 | - | - |
Ylin
0,075VWAP
Alin
0,072VaihtoMäärä
0,5 6 543 851
VWAP
Ylin
0,075Alin
0,072VaihtoMäärä
0,5 6 543 851
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 25.3. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 26.11.2025 | |
| 2025 Q2 -tulosraportti | 17.9.2025 | |
| 2025 Q1 -tulosraportti | 27.6.2025 | |
| 2024 Q4 -tulosraportti | 26.3.2025 | |
| 2024 Q3 -tulosraportti | 27.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
47 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 25.3. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 26.11.2025 | |
| 2025 Q2 -tulosraportti | 17.9.2025 | |
| 2025 Q1 -tulosraportti | 27.6.2025 | |
| 2024 Q4 -tulosraportti | 26.3.2025 | |
| 2024 Q3 -tulosraportti | 27.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10 t sittenhttps://medwatch.no/nyheter/legemidler_biotek/article18894010.ece Article today 👌 Paywall, so attaching for those interested 👏 Spun-off companies. Change of main focus. Hard cost cuts. Now the management of Softox Solutions hopes to put some turbulent years behind them. The biotechnology company was established in 2012 and got a new CEO in 2024, when Thomas Bjarnsholt took office. The same year, biotech veteran Ulrik Spork took over as chairman of the board. In this interview, they explain why the company saw the need for a comprehensive strategic reorientation. The biggest change for the company was a change in the main indication the company wanted to test its platform on. From the acute disease ventilator-associated pneumonia (VAP) to the chronic cystic fibrosis. Both are diseases that affect our lungs. – Overall, we believe that the company can deliver on both chronic and acute indications. The challenge with acute lung patients is that they are very ill, often unconscious, and there are many complex factors that affect the picture, says chairman Spork. He says that when they analyzed the company's situation, there were too many uncertainties with VAP. – Should we risk a more expensive and longer study to reach an uncertain endpoint? Or should we go for more well-defined patient groups to prove the platform's effect? It was simply safer to go for cystic fibrosis. In addition, there are 20 years of experience with clinical studies within the disease, and patients can cough up samples that make it easier to measure whether Softox's solution actually kills bacteria. – It was about practical things that perhaps had not been thoroughly enough considered previously.
- ·1 päivä sittenhttps://docs.google.com/document/u/0/d/1sabf0reYnNUlkHiC2bG1EquCLwOxtgY16e-wecFsDRM/mobilebasic?pli=1 Interesting reading, taken from FA👌·13 t sittenFantastic, I've been saying that for a long time, if this breaks through/people understand how groundbreaking this is for humanity then this will explode, not just for my sake but humanity in general, but it helps that it helps me🍾, anyway have a nice day and good luck and take care of each other ❤️❤️
- 1 päivä sitten1 päivä sitten
- ·3 päivää sittenGot chat gpt to review various documents for SoftOx and create an analysis. A lottery stock that can actually succeed during 2026. Scenario Analysis 2026–2027 (straight to the point) Phase 2a fails / unclear signal Probability: ~25 % Price: 0.03–0.05 What happens: Lung is difficult The market loses faith Classic biotech slaughter This is the downside. It is ugly, but limited. Phase 2a OK / positive, but not wow Probability: ~45 % Price: 0.20–0.35 What happens: Repricing, not hype New floor in the stock SoftOx becomes a “real company”, not hope . Phase 2a clearly positive + military contract Probability: ~25 % Price: 0.50–1.00+ What happens: EU/NATO-stockpiling De-risking deluxe Big Pharma starts to smell money this is the jackpot scenario. Not sci-fi. Full success (rare, but possible) Probability: ~5 % Price: 1.50–3.00 What happens: Partner agreement Global AMR-case·2 päivää sittenWhat does it base the probability of failure on/how is it prompted in this case? Has it taken into account that SoftOx has already completed phase 2a on SBE, successfully? The research on SIS is based on the same chemistry/composition, and chemistry tends to remain similar through phases from 2a-3a, in several such cases as this case is based on.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
382 768
Myynti
Määrä
189 300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 902 | - | - | ||
| 40 000 | - | - | ||
| 12 818 | - | - | ||
| 58 442 | - | - | ||
| 200 000 | - | - |
Ylin
0,075VWAP
Alin
0,072VaihtoMäärä
0,5 6 543 851
VWAP
Ylin
0,075Alin
0,072VaihtoMäärä
0,5 6 543 851
Välittäjätilasto
Dataa ei löytynyt